Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

2(66.7%)

Phase 2

1(33.3%)

3Total

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05043103Active Not Recruiting

Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

Role: lead

NCT07313176Recruiting

Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease

Role: lead

NCT00346827Phase 2Completed

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

Role: lead

NCT02006121Phase 3Completed

Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease

Role: lead

NCT00032942Phase 3Completed

Lofexidine for Opiate Withdrawal - 1

Role: collaborator

All 5 trials loaded